Get started
NOVO-NORDISK ASNOVO-NORDISK ASNOVO-NORDISK AS

NOVO-NORDISK AS

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

NNO2 chart


Full chart

Key facts today


Amgen has launched its anti-obesity candidate, MariTide, currently in Phase 2 trials, to compete with Novo Nordisk's offerings in the obesity drug market.
Analyze the impactAnalyze the impact

NNO2 upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪355.82 B‬ EUR
Dividend yield (indicated)
1.90%
Price to earnings Ratio (TTM)
26.73
Basic EPS (TTM)
3.03 EUR
Net income (FY)
‪13.50 B‬ EUR
Revenue (FY)
‪38.82 B‬ EUR
Shares float
‪3.15 B‬
Beta (1Y)
1.43

Employees


Employees (FY)
‪76.3 K‬
Change (1Y)
‪+12.93 K‬ +20.41%
Revenue / Employee (1Y)
‪508.83 K‬ EUR
Net income / Employee (1Y)
‪176.94 K‬ EUR

About NOVO NORDISK B A/S


Sector
Health Technology
CEO
Lars Fruergaard Jørgensen
Headquarters
Bagsværd
Website
novonordisk.com
Founded
1931
ISIN
DK0062498333
FIGI
BBG00KDZJQ50
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

NNO2 news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

NNO2 highest yielding bonds


N
XS282046075
NOVO NO.F.NL 24/34 MTN
Yield to maturity
3.20%
Maturity date
May 21, 2034
XS244124704
NOVO NO.F.NL 22/30MTN
Yield to maturity
2.93%
Maturity date
Mar 31, 2030
N
XS282045567
NOVO NO.F.NL 24/31 MTN
Yield to maturity
2.93%
Maturity date
Jan 21, 2031
XS234803042
NOVO NO.F.NL 21/28
Yield to maturity
2.79%
Maturity date
Jun 4, 2028
N
XS282045460
NOVO NO.F.NL 24/29 MTN
Yield to maturity
2.78%
Maturity date
Jan 21, 2029
N
XS282044994
NOVO NO.F.NL 24/26 MTN
Yield to maturity
2.71%
Maturity date
May 21, 2026
XS244933017
NOVO NO.F.NL 22/27MTN
Yield to maturity
2.59%
Maturity date
Sep 30, 2027
XS244124453
NOVO NO.F.NL 22/25 MTN
Yield to maturity
2.56%
Maturity date
Mar 31, 2025

Explore more bonds 

Sparks


Curated watchlists where NNO2 is featured.

See all sparks 

Frequently Asked Questions


The current price of NNO2 is 78.62 EUR — it has decreased by −2.04% in the past 24 hours. Watch NOVO-NORDISK AS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on VIE exchange NOVO-NORDISK AS stocks are traded under the ticker NNO2.
NNO2 stock has fallen by −4.70% compared to the previous week, the month change is a −5.11% fall, over the last year NOVO-NORDISK AS has showed a −29.89% decrease.
We've gathered analysts' opinions on NOVO-NORDISK AS future price: according to them, NNO2 price has a max estimate of 153.77 EUR and a min estimate of 68.86 EUR. Watch NNO2 chart and read a more detailed NOVO-NORDISK AS stock forecast: see what analysts think of NOVO-NORDISK AS and suggest that you do with its stocks.
NNO2 reached its all-time high on Jun 25, 2024 with the price of 137.98 EUR, and its all-time low was 17.95 EUR and was reached on Oct 11, 2018. View more price dynamics on NNO2 chart.
See other stocks reaching their highest and lowest prices.
NNO2 stock is 3.75% volatile and has beta coefficient of 1.43. Track NOVO-NORDISK AS stock price on the chart and check out the list of the most volatile stocks — is NOVO-NORDISK AS there?
Today NOVO-NORDISK AS has the market capitalization of ‪357.40 B‬, it has decreased by −3.38% over the last week.
Yes, you can track NOVO-NORDISK AS financials in yearly and quarterly reports right on TradingView.
NOVO-NORDISK AS is going to release the next earnings report on May 7, 2025. Keep track of upcoming events with our Earnings Calendar.
NNO2 earnings for the last quarter are 0.85 EUR per share, whereas the estimation was 0.80 EUR resulting in a 6.08% surprise. The estimated earnings for the next quarter are 0.86 EUR per share. See more details about NOVO-NORDISK AS earnings.
NOVO-NORDISK AS revenue for the last quarter amounts to ‪11.46 B‬ EUR, despite the estimated figure of ‪10.71 B‬ EUR. In the next quarter, revenue is expected to reach ‪10.87 B‬ EUR.
NNO2 net income for the last quarter is ‪3.77 B‬ EUR, while the quarter before that showed ‪3.66 B‬ EUR of net income which accounts for 3.14% change. Track more NOVO-NORDISK AS financial stats to get the full picture.
As of Feb 13, 2025, the company has ‪76.30 K‬ employees. See our rating of the largest employees — is NOVO-NORDISK AS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVO-NORDISK AS EBITDA is ‪19.99 B‬ EUR, and current EBITDA margin is 50.95%. See more stats in NOVO-NORDISK AS financial statements.
Like other stocks, NNO2 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVO-NORDISK AS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVO-NORDISK AS technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVO-NORDISK AS stock shows the sell signal. See more of NOVO-NORDISK AS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.